Crinetics Pharmaceuticals, Inc. (CRNX) · Insider trading
What Crinetics Pharmaceuticals's directors, officers and largest holders bought and sold themselves, from the Form 4 each of them files with the SEC within two business days of a trade. Open-market purchases and sales first: those are the trades somebody chose to make at the market price.
Bought, 12 months
$0
0 insiders, 0 trades
Sold, 12 months
$6.51M
8 insiders, 100% under a plan
Net, 12 months
−$6.51M
bought less sold
Latest filing
2026-09-01
filings read to 2026-10-19
Who traded, two years
| Insider | Bought | Sold | Trades | Last trade | Holds after |
|---|---|---|---|---|---|
| Knight Jeff E.Chief Dev. & Operating Officer | – | $4.06M | 6 | 2026-04-08 | 105,289 |
| Betz Stephen F.Chief Scientific Officer | – | $3.74M | 5 | 2026-03-16 | 141,342 |
| Pizzuti DanaChief Med and Dev Officer | – | $2.97M | 11 | 2025-12-01 | 66,837 |
| Struthers Richard ScottDirector, President & CEO | – | $2.17M | 6 | 2026-03-16 | 413,563 |
| Fust Matthew KDirector | – | $716,000 | 1 | 2025-09-26 | 22,836 |
| Okey StephanieDirector | – | $365,153 | 3 | 2026-06-17 | 7,008 |
| Vivaldi Coelho RogerioDirector | – | $300,761 | 3 | 2026-07-02 | 19,225 |
| Schilke TobinChief Financial Officer | – | $266,305 | 1 | 2026-03-03 | 78,121 |
| Kalofonos IsabelChief Commercial Officer | – | $137,500 | 1 | 2026-01-05 | 834 |
Open-market purchases and sales
Newest first. “Plan” marks a trade made under a 10b5-1 plan set up in advance.
| Date | Insider | Trade | Shares | Price | Value | Holds after | Filing |
|---|---|---|---|---|---|---|---|
| 2026-07-02 | Vivaldi Coelho RogerioDirector | Saleplan | 3,000 | 40.00 | $120,000 | 19,225 | Form 4 |
| 2026-06-17 | Okey StephanieDirector | Saleplan | 6,292 | 35.62 | $224,121 | 7,008 | Form 4 |
| 2026-06-17 | Okey StephanieDirector | Saleplan | 608 | 36.22 | $22,022 | 6,400 | Form 4 |
| 2026-04-08 | Knight Jeff E.Chief Dev. & Operating Officer | Saleplan | 85,163 | 40.10 | $3.42M | 105,289 | Form 4 |
| 2026-03-16 | Struthers Richard ScottDirector, President & CEO | Saleplan | 13,196 | 37.11 | $489,704 | 413,563 | Form 4 |
| 2026-03-16 | Struthers Richard ScottDirector, President & CEO | Saleplan | 8,785 | 37.77 | $331,809 | 404,778 | Form 4 |
| 2026-03-16 | Betz Stephen F.Chief Scientific Officer | Saleplan | 6,371 | 37.11 | $236,428 | 141,342 | Form 4 |
| 2026-03-16 | Betz Stephen F.Chief Scientific Officer | Saleplan | 4,241 | 37.77 | $160,183 | 137,101 | Form 4 |
| 2026-03-16 | Knight Jeff E.Chief Operating Officer | Saleplan | 5,950 | 37.11 | $220,804 | 115,979 | Form 4 |
| 2026-03-16 | Knight Jeff E.Chief Operating Officer | Saleplan | 3,961 | 37.77 | $149,607 | 112,018 | Form 4 |
| 2026-03-12 | Vivaldi Coelho RogerioDirector | Saleplan | 4,477 | 36.08 | $161,530 | 16,823 | Form 4 |
| 2026-03-12 | Vivaldi Coelho RogerioDirector | Saleplan | 523 | 36.77 | $19,231 | 16,300 | Form 4 |
| 2026-03-03 | Schilke TobinChief Financial Officer | Saleplan | 6,713 | 39.67 | $266,305 | 78,121 | Form 4 |
| 2026-03-03 | Okey StephanieDirector | Saleplan | 3,000 | 39.67 | $119,010 | 13,300 | Form 4 |
| 2026-01-05 | Kalofonos IsabelChief Commercial Officer | Saleplan | 2,500 | 55.00 | $137,500 | 834 | Form 4 |
| 2025-12-01 | Pizzuti DanaChief Med and Dev Officer | Saleplan | 5,000 | 45.02 | $225,100 | 66,837 | Form 4 |
| 2025-11-03 | Pizzuti DanaChief Med and Dev Officer | Saleplan | 4,900 | 42.65 | $208,985 | 66,370 | Form 4 |
| 2025-11-03 | Pizzuti DanaChief Med and Dev Officer | Saleplan | 100 | 43.27 | $4,327 | 66,270 | Form 4 |
| 2025-10-01 | Pizzuti DanaChief Med and Dev Officer | Saleplan | 5,000 | 41.81 | $209,050 | 66,270 | Form 4 |
| 2025-09-26 | Fust Matthew KDirector | Saleplan | 16,000 | 44.75 | $716,000 | 22,836 | Form 4 |
| 2025-09-26 | Struthers Richard ScottDirector, President & CEO | Saleplanindirect | 4,000 | 45.00 | $180,000 | 106,000 | Form 4 |
| 2025-09-02 | Pizzuti DanaChief Med and Dev Officer | Saleplan | 5,000 | 32.10 | $160,500 | 96,270 | Form 4 |
| 2025-08-22 | Pizzuti DanaChief Med and Dev Officer | Saleplan | 30,000 | 30.43 | $912,900 | 66,270 | Form 4 |
| 2025-08-20 | Pizzuti DanaChief Med and Dev Officer | Saleplan | 6,492 | 29.18 | $189,437 | 66,270 | Form 4 |
| 2025-06-12 | Betz Stephen F.Chief Scientific Officer | Saleplan | 97,483 | 32.23 | $3.14M | 99,713 | Form 4 |
| 2025-03-19 | Struthers Richard ScottDirector, President & CEO | Saleplan | 16,463 | 34.17 | $562,541 | 330,022 | Form 4 |
| 2025-03-19 | Struthers Richard ScottDirector, President & CEO | Saleplan | 875 | 34.83 | $30,476 | 329,147 | Form 4 |
| 2025-03-19 | Betz Stephen F.Chief Scientific Officer | Saleplan | 5,479 | 34.17 | $187,217 | 108,879 | Form 4 |
| 2025-03-19 | Betz Stephen F.Chief Scientific Officer | Saleplan | 291 | 34.83 | $10,136 | 108,588 | Form 4 |
| 2025-03-19 | Knight Jeff E.Chief Operating Officer | Saleplan | 6,801 | 34.17 | $232,390 | 87,852 | Form 4 |
| 2025-03-19 | Knight Jeff E.Chief Operating Officer | Saleplan | 361 | 34.83 | $12,574 | 87,491 | Form 4 |
| 2025-03-19 | Pizzuti DanaChief Med and Dev Officer | Saleplan | 2,388 | 34.17 | $81,598 | 72,360 | Form 4 |
| 2025-03-19 | Pizzuti DanaChief Med and Dev Officer | Saleplan | 127 | 34.83 | $4,423 | 72,233 | Form 4 |
| 2025-02-03 | Pizzuti DanaChief Med and Dev Officer | Saleplan | 5,000 | 39.07 | $195,350 | 31,748 | Form 4 |
| 2025-01-03 | Pizzuti DanaChief Med and Dev Officer | Saleplan | 15,000 | 52.09 | $781,350 | 29,248 | Form 4 |
| 2024-12-02 | Struthers Richard ScottDirector, President & CEO | Saleplanindirect | 10,000 | 57.57 | $575,700 | 100,000 | Form 4 |
| 2024-11-22 | Knight Jeff E.Chief Operating Officer | Saleplan | 501 | 56.52 | $28,317 | 51,653 | Form 4 |
Grants, exercises and other transactions
Pay, tax and paperwork rather than a choice to trade at the market price. Two years.
32 × returned to the company25 × grant or award24 × option exercise16 × gift2 × other
Show them
| Date | Insider | What | Shares | Price | Holds after | Filing |
|---|---|---|---|---|---|---|
| 2026-09-01 | Struthers Richard ScottDirector, President & CEO | Returned to the company D | −248,043 | 85.00 | 176,663 | Form 4 |
| 2026-09-01 | Struthers Richard ScottDirector, President & CEO | Returned to the company D | −1,000 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Struthers Richard ScottDirector, President & CEO | Returned to the company D | −136,805 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Struthers Richard ScottDirector, President & CEO | Returned to the company D | −106,000 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Struthers Richard ScottDirector, President & CEO | Returned to the company D | −110,000 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Struthers Richard ScottDirector, President & CEO | Returned to the company D | −100,000 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Struthers Richard ScottDirector, President & CEO | Returned to the company D | −111,100 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Struthers Richard ScottDirector, President & CEO | Returned to the company D | −111,100 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Struthers Richard ScottDirector, President & CEO | Returned to the company D | −111,100 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Struthers Richard ScottDirector, President & CEO | Returned to the company D | −111,100 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Struthers Richard ScottDirector, President & CEO | Returned to the company D | −80,000 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Struthers Richard ScottDirector, President & CEO | Returned to the company D | −176,663 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Schilke TobinChief Financial & Infra. Ofcr. | Returned to the company D | −7,956 | 85.00 | 71,471 | Form 4 |
| 2026-09-01 | Schilke TobinChief Financial & Infra. Ofcr. | Returned to the company D | −71,471 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Betz Stephen F.Chief Scientific Officer | Returned to the company D | −58,286 | 85.00 | 79,650 | Form 4 |
| 2026-09-01 | Betz Stephen F.Chief Scientific Officer | Returned to the company D | −79,650 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Kalofonos IsabelChief Commercial Officer | Returned to the company D | −1,669 | 85.00 | 34,000 | Form 4 |
| 2026-09-01 | Kalofonos IsabelChief Commercial Officer | Returned to the company D | −34,000 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Bedrosian Camille LDirector | Returned to the company D | −16,300 | 85.00 | 5,925 | Form 4 |
| 2026-09-01 | Bedrosian Camille LDirector | Returned to the company D | −5,925 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Deardorf CarenDirector | Returned to the company D | −16,300 | 85.00 | 5,925 | Form 4 |
| 2026-09-01 | Deardorf CarenDirector | Returned to the company D | −5,925 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Fust Matthew KDirector | Returned to the company D | −22,836 | 85.00 | 5,925 | Form 4 |
| 2026-09-01 | Fust Matthew KDirector | Returned to the company D | −5,925 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Nichols WestonDirector | Returned to the company D | −16,300 | 85.00 | 5,925 | Form 4 |
| 2026-09-01 | Nichols WestonDirector | Returned to the company D | −5,925 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Okey StephanieDirector | Returned to the company D | −6,400 | 85.00 | 5,925 | Form 4 |
| 2026-09-01 | Okey StephanieDirector | Returned to the company D | −5,925 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Vivaldi Coelho RogerioDirector | Returned to the company D | −13,300 | 85.00 | 5,925 | Form 4 |
| 2026-09-01 | Vivaldi Coelho RogerioDirector | Returned to the company D | −5,925 | 85.00 | 0 | Form 4 |
| 2026-09-01 | Wierenga WendellDirector | Returned to the company D | −116,146 | 85.00 | 5,925 | Form 4 |
| 2026-09-01 | Wierenga WendellDirector | Returned to the company D | −5,925 | 85.00 | 0 | Form 4 |
| 2026-08-20 | Schilke TobinChief Financial & Infra. Ofcr. | Grant or award A | +471 | – | 79,427 | Form 4 |
| 2026-08-07 | Struthers Richard ScottDirector, President & CEO | Option exercise M | +3,969 | 25.19 | 408,747 | Form 4 |
| 2026-08-07 | Struthers Richard ScottDirector, President & CEO | Option exercise M | +4,422 | 22.61 | 413,169 | Form 4 |
| 2026-08-07 | Struthers Richard ScottDirector, President & CEO | Option exercise M | +6,542 | 15.29 | 419,711 | Form 4 |
| 2026-08-07 | Struthers Richard ScottDirector, President & CEO | Option exercise M | +4,995 | 20.02 | 424,706 | Form 4 |
| 2026-06-18 | Okey StephanieDirector | Grant or award A | +5,925 | – | 12,325 | Form 4 |
| 2026-06-18 | Wierenga WendellDirector | Grant or award A | +5,925 | – | 122,071 | Form 4 |
| 2026-06-18 | Bedrosian Camille LDirector | Grant or award A | +5,925 | – | 22,225 | Form 4 |
| 2026-06-18 | Vivaldi Coelho RogerioDirector | Grant or award A | +5,925 | – | 22,225 | Form 4 |
| 2026-06-18 | Nichols WestonDirector | Grant or award A | +5,925 | – | 22,225 | Form 4 |
| 2026-06-18 | Fust Matthew KDirector | Grant or award A | +5,925 | – | 28,761 | Form 4 |
| 2026-06-18 | Deardorf CarenDirector | Grant or award A | +5,925 | – | 22,225 | Form 4 |
| 2026-05-29 | Struthers Richard ScottDirector, President & CEO | Gift G | −222,200 | – | 439,005 | Form 4 |
| 2026-05-29 | Struthers Richard ScottDirector, President & CEO | Gift G | −222,200 | – | 216,805 | Form 4 |
| 2026-05-29 | Struthers Richard ScottDirector, President & CEO | Gift G | −80,000 | – | 136,805 | Form 4 |
| 2026-05-29 | Struthers Richard ScottDirector, President & CEO | Gift G | +222,200 | – | 626,978 | Form 4 |
| 2026-05-29 | Struthers Richard ScottDirector, President & CEO | Gift G | +222,200 | – | 223,200 | Form 4 |
| 2026-05-29 | Struthers Richard ScottDirector, President & CEO | Gift G | +80,000 | – | 80,000 | Form 4 |
| 2026-05-29 | Struthers Richard ScottDirector, President & CEO | Gift G | −111,100 | – | 515,878 | Form 4 |
| 2026-05-29 | Struthers Richard ScottDirector, President & CEO | Gift G | −111,100 | – | 404,778 | Form 4 |
| 2026-05-29 | Struthers Richard ScottDirector, President & CEO | Gift G | +111,100 | – | 111,100 | Form 4 |
| 2026-05-29 | Struthers Richard ScottDirector, President & CEO | Gift G | +111,100 | – | 111,100 | Form 4 |
| 2026-05-29 | Struthers Richard ScottDirector, President & CEO | Gift G | −111,100 | – | 112,100 | Form 4 |
| 2026-05-29 | Struthers Richard ScottDirector, President & CEO | Gift G | −111,100 | – | 1,000 | Form 4 |
| 2026-05-29 | Struthers Richard ScottDirector, President & CEO | Gift G | +111,100 | – | 111,100 | Form 4 |
| 2026-05-29 | Struthers Richard ScottDirector, President & CEO | Gift G | +111,100 | – | 111,100 | Form 4 |
| 2026-04-08 | Knight Jeff E.Chief Dev. & Operating Officer | Option exercise M | +49,474 | 23.98 | 161,492 | Form 4 |
| 2026-04-08 | Knight Jeff E.Chief Dev. & Operating Officer | Option exercise M | +9,624 | 20.02 | 171,116 | Form 4 |
| 2026-04-08 | Knight Jeff E.Chief Dev. & Operating Officer | Option exercise M | +19,336 | 19.64 | 190,452 | Form 4 |
| 2026-02-23 | Kalofonos IsabelChief Commercial Officer | Grant or award A | +34,000 | – | 34,834 | Form 4 |
| 2026-02-23 | Betz Stephen F.Chief Scientific Officer | Grant or award A | +30,000 | – | 147,713 | Form 4 |
| 2026-02-23 | Knight Jeff E.Chief Operating Officer | Grant or award A | +34,000 | – | 121,929 | Form 4 |
| 2026-02-23 | Schilke TobinChief Financial Officer | Grant or award A | +32,000 | – | 84,834 | Form 4 |
| 2026-02-23 | Struthers Richard ScottDirector, President & CEO | Grant or award A | +62,000 | – | 426,759 | Form 4 |
| 2026-01-05 | Kalofonos IsabelChief Commercial Officer | Option exercise M | +2,500 | 40.59 | 3,334 | Form 4 |
| 2025-12-26 | Betz Stephen F.Chief Scientific Officer | Option exercise M | +18,000 | 1.91 | 117,713 | Form 4 |
| 2025-12-18 | Struthers Richard ScottDirector, President & CEO | Option exercise M | +16,342 | 9.28 | 336,359 | Form 4 |
| 2025-12-18 | Struthers Richard ScottDirector, President & CEO | Option exercise M | +28,400 | 15.29 | 364,759 | Form 4 |
| 2025-12-01 | Pizzuti DanaChief Med and Dev Officer | Option exercise M | +5,000 | 16.89 | 71,837 | Form 4 |
| 2025-11-03 | Pizzuti DanaChief Med and Dev Officer | Option exercise M | +5,000 | 16.89 | 71,270 | Form 4 |
| 2025-10-01 | Pizzuti DanaChief Med and Dev Officer | Option exercise M | +5,000 | 16.89 | 71,270 | Form 4 |
| 2025-09-26 | Fust Matthew KDirector | Option exercise M | +10,000 | 1.91 | 38,836 | Form 4 |
| 2025-09-02 | Pizzuti DanaChief Med and Dev Officer | Option exercise M | +5,000 | 16.89 | 101,270 | Form 4 |
| 2025-08-22 | Pizzuti DanaChief Med and Dev Officer | Option exercise M | +30,000 | 16.89 | 96,270 | Form 4 |
| 2025-06-12 | Betz Stephen F.Chief Scientific Officer | Option exercise M | +71,525 | 1.91 | 180,551 | Form 4 |
| 2025-06-12 | Betz Stephen F.Chief Scientific Officer | Option exercise M | +16,645 | 9.28 | 197,196 | Form 4 |
| 2025-06-11 | Wierenga WendallDirector | Grant or award A | +6,900 | – | 116,146 | Form 4 |
| 2025-06-11 | Nichols WestonDirector | Grant or award A | +6,900 | – | 16,300 | Form 4 |
| 2025-06-11 | Bedrosian Camille LDirector | Grant or award A | +6,900 | – | 16,300 | Form 4 |
| 2025-06-11 | Fust Matthew KDirector | Grant or award A | +6,900 | – | 28,836 | Form 4 |
| 2025-06-11 | Okey StephanieDirector | Grant or award A | +6,900 | – | 16,300 | Form 4 |
| 2025-06-11 | Vivaldi Coelho RogerioDirector | Grant or award A | +6,900 | – | 21,300 | Form 4 |
| 2025-06-11 | Deardorf CarenDirector | Grant or award A | +6,900 | – | 16,300 | Form 4 |
| 2025-05-14 | Struthers Richard ScottDirector, President & CEO | Gift G | −90,400 | – | 320,017 | Form 4 |
| 2025-05-14 | Struthers Richard ScottDirector, President & CEO | Gift G | +90,400 | – | 661,205 | Form 4 |
| 2025-04-02 | Struthers Richard ScottDirector, President & CEO | Option exercise M | +81,270 | 1.91 | 410,417 | Form 4 |
| 2025-03-10 | Schilke TobinChief Financial Officer | Grant or award A | +52,000 | – | 52,000 | Form 4 |
| 2025-02-20 | Betz Stephen F.Chief Scientific Officer | Grant or award A | +43,000 | – | 114,358 | Form 4 |
| 2025-02-20 | Pizzuti DanaChief Med and Dev Officer | Grant or award A | +43,000 | – | 74,748 | Form 4 |
| 2025-02-20 | Knight Jeff E.Chief Operating Officer | Grant or award A | +43,000 | – | 94,653 | Form 4 |
| 2025-02-20 | Struthers Richard ScottDirector, President & CEO | Grant or award A | +89,000 | – | 346,485 | Form 4 |
| 2025-02-03 | Pizzuti DanaChief Med and Dev Officer | Option exercise M | +5,000 | 16.89 | 36,748 | Form 4 |
| 2025-01-07 | Pizzuti DanaChief Med and Dev Officer | Option exercise M | +2,500 | 19.64 | 31,748 | Form 4 |
| 2025-01-03 | Pizzuti DanaChief Med and Dev Officer | Option exercise M | +15,000 | 16.89 | 44,248 | Form 4 |
| 2024-12-16 | Betz Stephen F.Chief Scientific Officer | Option exercise M | +2,331 | 1.91 | 71,358 | Form 4 |
| 2024-11-20 | Wilson MarcCFO | Other J | +473 | 14.98 | 111,565 | Form 5 |
| 2024-11-20 | Betz Stephen F.Chief Scientific Officer | Other J | +451 | 14.98 | 71,358 | Form 5 |
How to read it
- Buy, sale
- Code P and S on the form: shares bought or sold in the market, at the market price. The other codes are mostly pay (a grant, an option exercised) or tax (shares the company withheld), and say little about what the insider thinks of the price.
- Plan
- A sale or purchase under a Rule 10b5-1 plan, set up in advance and running on its own schedule. Since April 2023 the form has a box for it. Much executive selling is planned and says more about diversifying than about the company.
- Holds after
- The shares the insider still held after the trade, in the form the trade was in (directly, or indirectly through a trust or a fund).
- Value
- Shares times the price the form reports, which is often an average over several fills on the day.
Read from the SEC's own quarterly data sets of Forms 3, 4 and 5, and from each day's filings since the last one. A correcting amendment replaces the lines it restates. Every row links to its filing. None of this is advice: insiders sell for many reasons, and buy for fewer.